This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of 44.44% and 4.06%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Gritstone bio Inc. (GRTS) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Gritstone bio Inc. (GRTS) delivered earnings and revenue surprises of 6.25% and 38.93%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Is Attractively Priced Despite Fast-paced Momentum
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
PetIQ (PETQ) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
PetIQ (PETQ) delivered earnings and revenue surprises of 28.57% and 4.23%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Insulet (PODD) delivered earnings and revenue surprises of 155.56% and 8.45%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Shows Fast-paced Momentum But Is Still a Bargain Stock
by Zacks Equity Research
Rockwell Medical (RMTI) made it through our 'Fast-Paced Momentum at a Bargain' screen and could be a great choice for investors looking for stocks that have gained strong momentum recently but are still trading at reasonable prices.
Palo Alto Networks and RH have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Palo Alto Networks and RH are part of the Zacks Bull and Bear of the Day article.
3 Medical Product Stocks With Strong Potential to Gain in 2023
by Indrajit Bandyopadhyay
Here we discuss three medical instruments stocks, LNTH, RMTI and VMD, which are witnessing solid momentum in 2023. These stocks have the potential to continue their uptrend going forward.
Here Is Why Bargain Hunters Would Love Fast-paced Mover Rockwell Medical (RMTI)
by Zacks Equity Research
Rockwell Medical (RMTI) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Beat the Market Like Zacks: NVIDIA, Boeing, Rockwell Medical in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Beat the Market the Zacks Way: NVIDIA, Bilibili, Novo Nordisk in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.
Capricor Therapeutics (CAPR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Capricor (CAPR) delivered earnings and revenue surprises of 7.14% and 279.05%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Why Fast-paced Mover Rockwell Medical (RMTI) Is a Great Choice for Value Investors
by Zacks Equity Research
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Rockwell Medical (RMTI) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
IM Cannabis Corp. (IMCC) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
IM Cannabis Corp. (IMCC) delivered earnings and revenue surprises of -550% and 6.69%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Perrigo (PRGO) Q1 Earnings Lag Estimates
by Zacks Equity Research
Perrigo (PRGO) delivered earnings and revenue surprises of -21.43% and 1.66%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Maravai LifeSciences Holdings, Inc. (MRVI) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Maravai LifeSciences Holdings, Inc. (MRVI) delivered earnings and revenue surprises of 25.58% and 6.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Lantheus Holdings (LNTH) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Lantheus Holdings (LNTH) delivered earnings and revenue surprises of 110.87% and 26.26%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Quanterix Corporation (QTRX) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Quanterix Corporation (QTRX) delivered earnings and revenue surprises of 20.29% and 1.08%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -14.29% and -11.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Rockwell Medical (RMTI) Report Negative Q3 Earnings? What You Should Know
by Zacks Equity Research
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rockwell Medical (RMTI) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -11.64%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Rockwell Medical (RMTI)
by Zacks Equity Research
Rockwell Medical (RMTI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Rockwell Medical (RMTI) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Rockwell Medical (RMTI) delivered earnings and revenue surprises of -12.50% and -5.34%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Rockwell Medical (RMTI) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Rockwell Medical (RMTI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.